The ansamycin antibiotic, Rifamycin SV, inhibits BCL6 transcriptional repression and forms a complex with the BCL6-BTB/POZ domain

Evans, S. E., Goult, B. T., Fairall, L., Jamieson, A. G. , Ko Ferrigno, P., Ford, R., Schwabe, J. W.R. and Wagner, S. D. (2014) The ansamycin antibiotic, Rifamycin SV, inhibits BCL6 transcriptional repression and forms a complex with the BCL6-BTB/POZ domain. PLoS ONE, 9(3), e90889. (doi: 10.1371/journal.pone.0090889) (PMID:24595451) (PMCID:PMC3942486)

[img]
Preview
Text
130874.pdf - Published Version
Available under License Creative Commons Attribution.

3MB

Abstract

BCL6 is a transcriptional repressor that is over-expressed due to chromosomal translocations, or other abnormalities, in ∼40% of diffuse large B-cell lymphoma. BCL6 interacts with co-repressor, SMRT, and this is essential for its role in lymphomas. Peptide or small molecule inhibitors, which prevent the association of SMRT with BCL6, inhibit transcriptional repression and cause apoptosis of lymphoma cells in vitro and in vivo. In order to discover compounds, which have the potential to be developed into BCL6 inhibitors, we screened a natural product library. The ansamycin antibiotic, rifamycin SV, inhibited BCL6 transcriptional repression and NMR spectroscopy confirmed a direct interaction between rifamycin SV and BCL6. To further determine the characteristics of compounds binding to BCL6-POZ we analyzed four other members of this family and showed that rifabutin, bound most strongly. An X-ray crystal structure of the rifabutin-BCL6 complex revealed that rifabutin occupies a partly non-polar pocket making interactions with tyrosine58, asparagine21 and arginine24 of the BCL6-POZ domain. Importantly these residues are also important for the interaction of BLC6 with SMRT. This work demonstrates a unique approach to developing a structure activity relationship for a compound that will form the basis of a therapeutically useful BCL6 inhibitor.

Item Type:Articles
Additional Information:SEE is supported by a University of Leicester PhD Studentship (http://www.le.ac.uk). The work is supported by a Wellcome Trust Programme Grant WT091820 and Senior Investigator Grant WT100237 to JWRS.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Jamieson, Professor Andrew
Authors: Evans, S. E., Goult, B. T., Fairall, L., Jamieson, A. G., Ko Ferrigno, P., Ford, R., Schwabe, J. W.R., and Wagner, S. D.
College/School:College of Science and Engineering > School of Chemistry
Journal Name:PLoS ONE
Publisher:Public Library of Science
ISSN:1932-6203
ISSN (Online):1932-6203
Published Online:04 March 2014
Copyright Holders:Copyright © 2014 Evans et al.
First Published:First published in PLoS ONE 9(3):e90889
Publisher Policy:Reproduced under a creative commons license

University Staff: Request a correction | Enlighten Editors: Update this record